PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 152 filers reported holding PDL BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $4,000 | 0.0% | 1,124 | 0.0% | 0.00% | – |
| Q1 2020 | $4,000 | 0.0% | 1,124 | 0.0% | 0.00% | – |
| Q4 2019 | $4,000 | -98.6% | 1,124 | -99.2% | 0.00% | -100.0% |
| Q3 2019 | $295,000 | -31.2% | 136,330 | 0.0% | 0.00% | -40.0% |
| Q2 2019 | $429,000 | -15.6% | 136,330 | 0.0% | 0.01% | -16.7% |
| Q1 2019 | $508,000 | +28.3% | 136,330 | 0.0% | 0.01% | +20.0% |
| Q4 2018 | $396,000 | +10.3% | 136,330 | 0.0% | 0.01% | +66.7% |
| Q3 2018 | $359,000 | +12.5% | 136,330 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $319,000 | -13.3% | 136,330 | +9.0% | 0.00% | -25.0% |
| Q1 2018 | $368,000 | +1372.0% | 125,040 | +1243.9% | 0.00% | – |
| Q4 2017 | $25,000 | +19.0% | 9,304 | +53.2% | 0.00% | – |
| Q3 2017 | $21,000 | +40.0% | 6,075 | 0.0% | 0.00% | – |
| Q2 2017 | $15,000 | +7.1% | 6,075 | 0.0% | 0.00% | – |
| Q1 2017 | $14,000 | -86.4% | 6,075 | -87.5% | 0.00% | -100.0% |
| Q4 2016 | $103,000 | -96.2% | 48,641 | -94.1% | 0.00% | -95.2% |
| Q3 2016 | $2,742,000 | -28.6% | 818,536 | -33.0% | 0.02% | -36.4% |
| Q2 2016 | $3,838,000 | +15.0% | 1,222,251 | +22.0% | 0.03% | +3.1% |
| Q1 2016 | $3,338,000 | +11410.3% | 1,002,254 | +12118.1% | 0.03% | – |
| Q4 2015 | $29,000 | -98.4% | 8,203 | -97.7% | 0.00% | -100.0% |
| Q3 2015 | $1,805,000 | +7747.8% | 358,783 | +9913.5% | 0.02% | – |
| Q2 2015 | $23,000 | -99.3% | 3,583 | -99.2% | 0.00% | -100.0% |
| Q1 2015 | $3,071,000 | -31.8% | 436,483 | -25.2% | 0.04% | -32.7% |
| Q4 2014 | $4,501,000 | -78.5% | 583,784 | -79.2% | 0.05% | -90.8% |
| Q3 2014 | $20,964,000 | +63.2% | 2,806,400 | +111.5% | 0.56% | +63.7% |
| Q2 2014 | $12,844,000 | +390.6% | 1,326,900 | +321.2% | 0.34% | +335.4% |
| Q1 2014 | $2,618,000 | -65.3% | 315,000 | -64.8% | 0.08% | -72.5% |
| Q4 2013 | $7,547,000 | +44.9% | 894,100 | +36.8% | 0.29% | +27.6% |
| Q3 2013 | $5,207,000 | -24.4% | 653,400 | -26.7% | 0.22% | -7.0% |
| Q2 2013 | $6,884,000 | – | 891,600 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |